Here, we study the mechanisms and localization of IgG/PLG binding in patients with prostate cancer (PC), patients with benign prostate hyperplasia (BPH), and healthy controls, to ascertain the usability of IgG-Lys as a potential biomarker of PC. This evidence concerns the gene PLG and pachyonychia congenita.